Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03932279 · ClinicalTrials.gov registry record
Characterization of the Microbiome in Cutaneous T Cell Lymphoma
A clinical trial of Cutaneous T Cell Lymphoma, sponsored by Northwestern University.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT03932279: Recruiting study of Cutaneous T Cell Lymphoma, sponsored by Northwestern University.
NCT03932279 is a study of Cutaneous T Cell Lymphoma that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 300 participants, above the 55-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (445% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03932279, a study of Cutaneous T Cell Lymphoma, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators plan to perform a pilot study that aims to characterize the microbiome of human cutaneous T cell lymphoma patients and compare this to the microbiome of age and sex matched controls.
Primary Outcome
Diversity analysis of microbiome samples (measured by number of bacteria species/sample)
Conditions Studied
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2019-01-30 |
| Est. Completion | 2028-08-31 |
What NCT03932279 shows while recruiting
NCT03932279 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 55-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (445% higher).
The record links to 1 condition, with Cutaneous T Cell Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT03932279 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT03932279 about?
NCT03932279 is a clinical study titled "Characterization of the Microbiome in Cutaneous T Cell Lymphoma". Investigators plan to perform a pilot study that aims to characterize the microbiome of human cutaneous T cell lymphoma patients and compare this to the microbiome of age and sex matched controls.
What is the current status of trial NCT03932279?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2019-01-30. Estimated completion is 2028-08-31.
What conditions does trial NCT03932279 study?
This clinical trial studies the following conditions: Cutaneous T Cell Lymphoma.
Who is sponsoring clinical trial NCT03932279?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03932279 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous T Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03932279's enrollment target sits among peer trials
300 1st of 23 higher than 23 of 23 other Cutaneous T Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cutaneous T Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Photopheresis in Early-stage Mycosis Fungoides
RECRUITING · Phase 2
-
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
RECRUITING · NA
-
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
RECRUITING · Phase 1
-
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
RECRUITING · Phase 1
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI